Combination treatment for newly diagnosed acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility, effectiveness, and safety of a combination treatment using chidamide, venetoclax, and azacitidine for patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy. The trial focuses on individuals aged 18 and older, specifically targeting those with certain comorbidities or age-related factors that make them ineligible for standard treatment options. By assessing the outcomes of this combination therapy, the study aims to provide a viable alternative for patients with limited treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* （1）Age ≥18 years old, no gender limit ;
* （2）be diagnosed with AML (non-M3) according to WHO 2016 standards;
* （3）No previous treatment;
* （4）Ineligible for intensive chemotherapy based on the following definitions: ≥75 years of age or 18 to 74 years of age with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3 A history of cardiac disease such as congestive heart failure Treatment is required, or ejection fraction ≤ 50%, or chronic stable angina, diffusing capacity of lung for carbon monoxide (DLCO) ≤ 65%, or forced expiratory volume in first second (FEV1) ≤ 65%, creatinine clearance ≥ 30 mL/min to \< 45 mL/min, moderate hepatic impairment, total bilirubin \> 1.5 to ≤ 3.0 × ULN, other comorbidities that are not suitable for intensive chemotherapy in the physician's judgment.
* （5）Subjects must have an ECOG performance status score of: 0 to 2 for subjects aged ≥ 75 years or 0 to 3 for subjects aged ≥ 18 to 74 years.
* （6）Other comorbidities that are not suitable for intensive chemotherapy in the doctor's judgment;
* （7）Expected survival time ≥3 months;
* （8）Have the ability to understand and be willing to sign the informed consent form for this study.

Exclusion Criteria:

* (1) Combined with other malignant tumors
* (2) Have ever received treatment with chidamide and / or venetoclax or azacitidine;
* (3) The risk is assessed as low risk according to the NCCN 2022 guidelines \[t(8;21)(q22;q22.1);RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16 )(p13.1;q22);CBFB-MYH11 \] ;
* (4) The subject is known to have AML central nervous system (CNS) infiltration;
* (5) Have undergone cardiac angioplasty or stent placement within 12 months before signing the informed consent form , or have a history of myocardial infarction, unstable angina, or other clinically significant heart disease;
* (6 ) Active infections (including bacterial, fungal or viral infections) and organ bleeding that cannot be controlled clinically;
* (7) Pregnant or lactating women;
* (8) Participated in any other clinical research within 3 months before signing the informed consent form ;
* (9 ) The researcher believes that it is not suitable to participate in this study;

Where it's running

• Blood Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Jianxiang Wang, MD — Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
• Study coordinator: Jianxiang Wang, Medical PhD
• Email: wangjx@ihcams.ac.cn
• Phone: 022-23909273

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• New treatment for patients with relapsed acute myeloid leukemia

  This study is testing a new treatment called CER-1236 to see if it can help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1 CERo Therapeutics Holdings, Inc. · Sacramento, California and 4 other locations · NCT06834282

• CAR-T cell therapy targeting CD33 and CD123 for treating acute myeloid leukemia

  This study is testing a new CAR-T cell therapy that targets specific markers in the blood to see if it can help people with acute myeloid leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06420063

• Combining revumenib with standard chemotherapy and targeted therapy for acute myeloid leukemia

  This study is testing a new treatment combining revumenib with standard chemotherapy and another targeted therapy to see if it helps newly diagnosed patients with a specific type of acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · New Haven, Connecticut and 1 other locations · NCT06313437

• Enhancing stem cell transplant for children with high-risk acute myeloid leukemia

  This study is testing a new way to improve stem cell transplants for children and young adults with high-risk acute myeloid leukemia by using half-matched family donors and special immune cells to make the treatment safer and more effective.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT06158828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.